Biologics Contract Manufacturing Market by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

As per Roots Analysis, the global biologics contract manufacturing market is estimated to grow from USD 22.2 billion in the current year to USD 58 billion by 2035, at a CAGR of 9.12% during the forecast period, till 2035.

The market sizing and opportunity analysis has been segmented across the following parameters:

Type of Service Offered

API Manufacturing
FDF Manufacturing

Type of Biologic Manufactured

Antibodies
Cell Therapies
Vaccines
Other Biologics

Type of Expression System Used

Mammalian
Microbial
Others

Scale of Operation

Preclinical / Clinical
Commercial

Company Size

Small
Mid-sized
Large and Very Large

Key Geographical Regions

North America
Europe
Asia-Pacific
Middle East and North Africa
Latin America

BIOLOGICS CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

Given the benefits offered by biological products, such as specificity, efficacy and safety, it has captured the attention of both industry stakeholders and patients. In fact, in 2023, the USFDA approved 17 biological products (including monoclonal antibodies and recombinant proteins). In addition, currently, several biologics are being investigated across different geographies for a myriad of disease indications, including immunological, oncological and rare disorders.

Despite the success of biopharmaceutical products, the production of biologics is a complex and cost intensive process coupled with multiple challenges, such as long development timelines, a high rate of attrition of pipeline drugs / therapies, regulatory and compliance-related issues, and inconsistencies related to the quality attributes of the final product. As a result, an increasing number of biopharmaceutical drug developers are relying on contract manufacturers for end-to-end solutions, including bioprocess development and optimization. As outsourcing gains wider acceptance as a practical and advantageous business model in this sector, the global market for biologics contract manufacturing is anticipated to experience significant growth throughout the forecast period.

BIOLOGICS CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

The report delves into the current state of the biologics contract manufacturing market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. Currently, more than 305 contract manufacturing organizations (CMOs) are engaged in the production of biologics; over 90% of such players provide FDF manufacturing services.
2. Around 70% of the stakeholders operate at all scales of operation to cater to the diverse needs of customers; notably, mammalian cell-based expression systems have emerged as a popular choice among CMOs.
3. The competition among service providers that claim to be focused on the niche and upcoming drug classes is fierce; it is primarily influenced by the success of several blockbuster therapies in the recent past.
4. In the past decade, a shift in trend has been observed in the biopharmaceutical contract manufacturing industry as more players have set up their manufacturing facilities in developing regions across Asia-Pacific.
5. Over the last five years, more than 695 deals have been inked by biologics CMOs; most of the collaborations were inked for the manufacturing of vaccines, antibodies and cell therapies.
6. In order to maintain a competitive edge and establish themselves as one-stop-shops, players are expanding their existing capabilities and service portfolios; the domain has witnessed over 135 mergers and acquisitions.
7. Considering the enormous opportunities associated with biologics contract manufacturing, investors have actively extended funds, amounting to USD 7.5 billion, across more than 90 funding instances in the past eight years.
8. Driven by the growing demand, CMOs have made elaborate investments to expand their existing capacities and capabilities, primarily for niche biologics; this trend is most pronounced in the US and China.
9. More than 215 initiatives were undertaken by big pharma players; more than 80% of such initiatives were focused on partnerships and expansions.
10. Though the existing installed capacity is sufficient to meet the current annual demand for biologics, we anticipate that CMOs are likely to invest in installing incremental capacity to meet the long-term demand.
11. The global installed biopharmaceutical contract manufacturing capacity is spread across various geographies; notably, large players account for 80% of the total capacity.
12. With the growing pipeline of biologics and the increased preference for outsourcing, the biopharmaceutical contract manufacturing services market is anticipated to witness steady growth in the foreseen future.
13. As more developers outsource various aspects of their respective manufacturing operations, we expect the biologics CMOs market to grow at an annualized rate of over 9% in the coming decade.

BIOLOGICS CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

Contract Manufacturing Market for API is Likely to Dominate the Biologics Contract Manufacturing Market During the Forecast Period

Based on the type of service(s) offered, the market is segmented into API and FDF. It is worth highlighting that majority of the current biologics contract manufacturing market is captured by APIs. This can be attributed to the fact that manufacturing of biopharmaceuticals API demand significant capital investments, which include facility costs (development and maintenance), material costs, labor costs and a number of other ancillary expenses. Therefore, stakeholders rely on the expertise of CMOs for API production.

Cell Therapies is the Fastest Growing Segment of the Biologics Contract Manufacturing Market During the Forecast Period

Based on the type of biologic manufactured, the market is segmented into antibodies, cell therapies, vaccines and other biologics. It is worth highlighting the antibodies capture the maximum share within the biopharmaceutical contract manufacturing market. This can be attributed to the fact that more than 100 antibodies have been approved across the globe and an increasing number of clinical trials related to antibodies are also underway.

Mammalian Expression System is Expected to Capture the Highest Share of the Biologics Contract Manufacturing Market During the Forecast Period

Based on the type of expression system used, the market is segmented into mammalian, microbial and others. It is worth highlighting that currently, the market is likely to be driven by revenues generated through biopharmaceutical projects employing mammalian expression systems. This can be attributed to the higher usage of such systems owing to their high protein yielding ability, enhanced folding and post-translational modifications, and improved batch-to-batch uniformity.

By Scale of Operation, Commercial Scale is Likely to Dominate the Biologics Contract Manufacturing Market During the Forecast Period

Based on the scale of operation, the market is segmented into preclinical / clinical and commercial scale. Whilst commercial scale manufacturing is projected to be the primary driver of the overall market, it is worth highlighting that the biologics manufacturing market at preclinical / clinical scale is likely to grow at a relatively higher CAGR.

Large and Very Large Companies Hold Maximum Share within the Biologics Manufacturing Market

Based on company size, the market is segmented into small companies, mid-sized, and large and very large companies. While large and very large companies account for a relatively higher market share, it is worth highlighting that the biologics contract manufacturing market for small companies is likely to witness substantial market growth in the coming years.

North America Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America. It is worth highlighting that over the years, the market in Asia-Pacific is expected to grow at a higher CAGR.

Example Players in the Biologics Contract Manufacturing Market

AGC Biologics
Boehringer Ingelheim
Catalent
Cell Therapies
Charles River Laboratories
FUJIFILM Diosynth Biotechnologies
KBI Biopharma
Kemwell Biopharma
Lonza
Miltenyi Biotec
Minaris Regenerative Medicine
Samsung Biologics
Sandoz
Vetter Pharma
Wuxi Biologics

Primary Research Overview

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of interviews held with the following industry stakeholders:

Chief Executive Officer, RoslinCT
Chief Executive Officer and Co-Founder, Jafral Biosolutions
Chief Technical Officer, Cell and Gene Therapy, Discovery Life Sciences
President, Bioworkshops
Senior Director, Global Strategic Marketing, Aldevron
Senior Director of Commercial Strategy and Market Insights, Resilience
Global Head of Sales and Marketing and Head of Business Development (Germany), Minaris Regenerative Medicine
Business Development Manager, 53Biologics
Manager Marketing and Sales, Richter-Helm BioLogics

BIOLOGICS CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

The report features an in-depth analysis of the biologics contract manufacturing market, focusing on key market segments, including type of service(s) offered, type of biologic manufactured, type of expression system used, scale of operation, company size and key geographical regions.
The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting market growth.
A comprehensive evaluation of companies offering contract manufacturing services for biologics, considering various parameters, such as year of establishment, company size (based on number of employees), location of headquarters, type of service offered (API and FDF manufacturing), type of biologic manufactured (antibody drug conjugates, antibodies, biosimilars, cell therapies, gene therapies, nucleic acids / oligonucleotides, plasmid DNA / viral vectors, proteins / peptides, vaccines and others), scale of operation (preclinical, clinical and commercial), type of expression system used (mammalian, microbial and others), type of bioreactor used (single-use and stainless steel) and mode of operation of bioreactor (batch, fed batch and continuous).
A comprehensive analysis of biopharmaceutical manufacturing facilities established across the key geographical regions (North America, Europe, Asia-Pacific and Rest of the World), highlighting the manufacturing hubs for biologics.
In-depth profiles of key biologics contract manufacturers based in North America, focusing on company overviews, service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
In-depth profiles of key biologics contract manufacturers based in Europe, focusing on company overviews, service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
In-depth profiles of key biologics contract manufacturers based in Asia-Pacific, focusing on company overviews, service portfolio, manufacturing facilities, recent developments, and an informed future outlook.
A comprehensive evaluation of the primary enablers within this industry, highlighting specific niche products such as antibody-drug conjugates (ADCs), bispecific antibodies, cell therapies, gene therapies, and viral vectors, which are likely to impact the growth of the contract services market.
A case study comparing the key characteristics of small and large molecule drugs, along with details on the various steps involved in their respective manufacturing processes.
An insightful framework that emphasizes the key indicators and factors that need to be considered by drug / therapy developers to determine whether to manufacture their respective products in-house or outsource the manufacturing operation to contract service providers.
Assessment of the various biopharmaceutical-focused manufacturing initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of biologic manufactured.
An analysis of partnerships established in this sector since 2018, based on several relevant parameters, such as year of partnership, type of partnership, type of biologic manufactured, therapeutic area, most active players (in terms of number of deals inked) and regional distribution of partnership activity.
A detailed analysis of the various mergers and acquisitions that have taken place within this industry, since 2018, based on several relevant parameters, such as year of agreement, type of deal, geographical location of companies, type of acquisition, type of biologic manufactured and key value drivers.
An examination of the different expansion efforts made by biologics contract manufacturers in this field to enhance their manufacturing capabilities, since 2016. This analysis considers various factors, including the year of expansion, purpose of expansion, type of biologic manufactured and location of expanded facility.
An analysis of the recent developments within the biologics contract manufacturing market, highlighting information on the funding investments made since 2016, along with information on the technology advancements related to biomanufacturing.
Estimation of global biopharmaceutical manufacturing capacity, derived from data provided by various industry stakeholders in the public domain. This analysis emphasizes the distribution of the available capacity on the basis of size of manufacturer (small, mid-sized, and large and very large), type of expression system used (mammalian, microbial and others) and geography (North America, Europe, Asia-Pacific and Rest of the World).
Informed estimates of the annual demand for biologics, taking into account the top 20 biologics, based on various relevant parameters, such as target patient population, dosing frequency and dose strength of the abovementioned products.
A company size-wise, detailed analysis of the total cost of ownership for biologics CMO for a period of 20 years.
A discussion on key drivers and challenges through a comprehensive SWOT analysis, which is likely to impact the growth of the overall market. This also includes a Harvey ball analysis that illustrates the relative impact of each element of the SWOT analysis on the overall biopharmaceutical industry.
A case study on the virtual business model concept, along with its role in the overall biopharmaceutical industry. It also features a discussion on the advantages and risks / challenges associated with outsourcing operations from virtual service providers.

KEY QUESTIONS ANSWERED IN THIS REPORT

How many companies are currently engaged in this market?
Which are the leading companies in this market?
What kind of partnership models are commonly adopted by industry stakeholders?
What is the current annual demand for biologics?
What kinds of expansion initiatives have been undertaken by industry stakeholders?
What are the factors that are likely to influence the evolution of this market?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

Complimentary PPT Insights Packs
Complimentary Excel Data Packs for all Analytical Modules in the Report
10% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100465

1. PREFACE

1.1. Biopharmaceutical Contract Manufacturing Market Overview
1.2. Key Market Insights
1.3. Scope of the Report
1.4. Research Methodology
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. COVID Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
- 3.2.1. Time Period
  - 3.2.1.1. Historical Trends
  - 3.2.1.2. Current and Forecasted Estimates
- 3.2.2. Currency Coverage
  - 3.2.2.1. Overview of Major Currencies Affecting the Market
  - 3.2.2.2. Impact of Currency Fluctuations on the Industry
- 3.2.3. Foreign Exchange Impact
  - 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
  - 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 3.2.4. Recession
  - 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
  - 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
- 3.2.5. Inflation
  - 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Overview of Biopharmaceuticals
5.3. Expression Systems for Biopharmaceuticals
- 5.3.1. Insect Expression Systems
- 5.3.2. Mammalian Expression Systems
- 5.3.3. Microbial Expression Systems
  - 5.3.3.1. Bacterial Expression Systems
  - 5.3.3.2. Fungal Expression Systems
  - 5.3.3.3. Yeast Expression Systems
- 5.3.4. Plant Expression Systems
- 5.3.5. Mammalian versus Microbial Expression Systems
5.4. Manufacturing Process of Biopharmaceuticals
- 5.4.1. Upstream Processing
- 5.4.2. Fermentation
- 5.4.3. Downstream Processing
5.5. Overview of Contract Manufacturing
5.6. Need for Outsourcing Biopharmaceutical Manufacturing Operations
- 5.6.1. Commonly Outsourced Manufacturing Operations for Biopharmaceuticals
- 5.6.2. Advantages of Outsourcing Biopharmaceutical Manufacturing Operations
- 5.6.3. Risks and Challenges Associated with Outsourcing Biopharmaceutical Manufacturing Operations
5.7. Key Considerations While Selecting a Contract Manufacturing Partner
5.8. Future Perspectives

6. MARKET LANDSCAPE

6.1. Chapter Overview
6.2. Biopharmaceutical Contract Manufacturers: Overall Market Landscape
- 6.2.1. Analysis by Year of Establishment
- 6.2.2. Analysis by Company Size
- 6.2.3. Analysis by Location of Headquarters
- 6.2.4. Analysis by Type of Service Offered
- 6.2.5. Analysis by Type of Biologic Manufactured
- 6.2.6. Analysis by Scale of Operation
- 6.2.7. Analysis by Type of Expression System Used
- 6.2.8. Analysis by Type of Bioreactor Used
- 6.2.9. Analysis by Mode of Operation of Bioreactor

7. REGIONAL CAPABILITY ANALYSIS

7.1. Chapter Overview
7.2. Key Assumptions and Parameter
7.3. Overview of Biopharmaceutical Contract Manufacturing Facilities
- 7.3.1. Analysis by Type of Service Offered
- 7.3.2. Analysis by Scale of Operation
7.4. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
7.5. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
7.6. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
7.7. Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World

8. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

8.1. Chapter Overview
8.2. Biopharmaceutical Contract Manufacturing in the US: Regulatory Scenario
8.3. Leading Biopharmaceutical CMOs in North America
- 8.3.1. AGC Biologics
  - 8.3.1.1. Company Overview
  - 8.3.1.2. Service Portfolio
    - 8.3.1.2.1. Process Development
    - 8.3.1.2.2. cGMP Manufacturing
    - 8.3.1.2.3. Quality and Regulatory Services
    - 8.3.1.2.4. Process Validation
  - 8.3.1.3. Financial Information
  - 8.3.1.4. Manufacturing Facilities
  - 8.3.1.5. Recent Developments and Future Outlook
- 8.3.2. Catalent
  - 8.3.2.1. Company Overview
  - 8.3.2.2. Service Portfolio
    - 8.3.2.2.1. Cell Line Development
    - 8.3.2.2.2. Biomanufacturing
    - 8.3.2.2.3. ADCs and Bioconjugates Manufacturing
    - 8.3.2.2.4. Biosimilars Development and Manufacturing
    - 8.3.2.2.5. Fill / Finish Solutions and Delivery Services
    - 8.3.2.2.6. Analytical Services
  - 8.3.2.3. Clinical Supply Services
  - 8.3.2.4. Financial Information
  - 8.3.2.5. Manufacturing Facilities
  - 8.3.2.6. Recent Developments and Future Outlook
- 8.3.3. FUJIFILM Diosynth Biotechnologies
  - 8.3.3.1. Company Overview
  - 8.3.3.2. Service Portfolio
    - 8.3.3.2.1. Strain Development
    - 8.3.3.2.2. Process Development
    - 8.3.3.2.3. cGMP Manufacturing
    - 8.3.3.2.4. Analytical Solutions
  - 8.3.3.3. Financial Information
  - 8.3.3.4. Manufacturing Facilities
  - 8.3.3.5. Recent Developments and Future Outlook
- 8.3.4. KBI Biopharma
  - 8.3.4.1. Company Overview
  - 8.3.4.2. Service Portfolio
    - 8.3.4.2.1. Process Development
    - 8.3.4.2.2. Analytical Development
    - 8.3.4.2.3. GMP Manufacturing
    - 8.3.4.2.4. Clinical Cell Therapy Support
  - 8.3.4.3. Manufacturing Facilities
  - 8.3.4.4. Recent Developments and Future Outlook
- 8.3.5. Charles River Laboratories
  - 8.3.5.1. Company Overview
  - 8.3.5.2. Service Portfolio
    - 8.3.5.2.1. Cell Sourcing
    - 8.3.5.2.2. Cell and Gene Therapy Solutions
    - 8.3.5.2.3. Biologics Testing Solutions
    - 8.3.5.2.4. Avian Vaccine Services
    - 8.3.5.2.5. QC Microbial Solutions
    - 8.3.5.2.6. Scientific and Regulatory Advisory Services
  - 8.3.5.3. Financial Information
  - 8.3.5.4. Manufacturing Facilities
  - 8.3.5.5. Recent Developments and Future Outlook
8.4. Other Leading Biopharmaceutical CMOs in North America
- 8.4.1. Cytiva
  - 8.4.1.1. Company Overview
- 8.4.2. Patheon
  - 8.4.2.1. Company Overview
- 8.4.3 Piramal Pharma Solutions
  - 8.4.3.1. Company Overview

9. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

9.1. Chapter Overview
9.2. Biopharmaceutical Contract Manufacturing in Europe: Regulatory Scenario
- 9.2.1. EMA's cGMP Regulations
9.3. Leading Biopharmaceutical CMOs in Europe
- 9.3.1. Boehringer Ingelheim (BioXcellence)
  - 9.3.1.1. Company Overview
  - 9.3.1.2. Service Portfolio
    - 9.3.1.2.1. Process Development
      - 9.3.1.2.1.1. Expression Systems
      - 9.3.1.2.1.2. Upstream Technology
      - 9.3.1.2.1.3. Downstream Technology
      - 9.3.1.2.1.4. Other Process Development Services
    - 9.3.1.2.2. Quality Assurance
    - 9.3.1.2.3. Fill / Finish Services
  - 9.3.1.3. Financial Information
  - 9.3.1.4. Manufacturing Facilities
  - 9.3.1.5. Recent Developments and Future Outlook
- 9.3.2. Lonza
  - 9.3.2.1. Company Overview
  - 9.3.2.2. Service Portfolio
  - 9.3.2.3. Manufacturing Services
  - 9.3.2.4. Financial Information
  - 9.3.2.5. Manufacturing Facilities
  - 9.3.2.6. Recent Developments and Future Outlook
- 9.3.3. Sandoz
  - 9.3.3.1. Company Overview
  - 9.3.3.2. Service Portfolio
  - 9.3.3.3. Financial Information
  - 9.3.3.4. Manufacturing Facilities
  - 9.3.3.5. Recent Developments and Future Outlook
- 9.3.4. Vetter Pharma
  - 9.3.4.1. Company Overview
  - 9.3.4.2. Service Portfolio
  - 9.3.4.3. Manufacturing Facilities
  - 9.3.4.4. Recent Developments and Future Outlook
- 9.3.5. Miltenyi Biotec
  - 9.3.5.1. Company Overview
  - 9.3.5.2. Service Portfolio
  - 9.3.5.3. Manufacturing Facilities
  - 9.3.5.4. Recent Developments and Future Outlook
9.4.Other Leading Biopharmaceutical CMOs in Europe
- 9.4.1. Novasep
  - 9.4.1.1. Company Overview
- 9.4.2 Olon
  - 9.4.2.1. Company Overview
- 9.4.3. Rentschler Biopharma
  - 9.4.3.1. Company Overview

10. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND REST OF THE WORLD

10.1. Chapter Overview
10.2. Biopharmaceutical Contract Manufacturing in China
- 10.2.1. Biopharmaceutical Contract Manufacturing in China: Regulatory Scenario
10.3. Leading Biopharmaceutical CMOs in China
- 10.3.1. WuXi Biologics
  - 10.3.1.1. Company Overview
  - 10.3.1.2. Service Portfolio
    - 10.3.1.2.1. Discovery Services
    - 10.3.1.2.2. Development Services
    - 10.3.1.2.3. Testing Services
    - 10.3.1.2.4. Clinical Manufacturing Services
  - 10.3.1.3. Financial Information
  - 10.3.1.4. Manufacturing Facilities
  - 10.3.1.5. Recent Developments and Future Outlook
10.4. Biopharmaceutical Contract Manufacturing in India
- 10.4.1. Biopharmaceutical Contract Manufacturing in India: Regulatory Scenario
10.5. Leading Biopharmaceutical CMOs in India
- 10.5.1. Kemwell Biopharma
  - 10.5.1.1. Company Overview
  - 10.5.1.2. Service Portfolio
    - 10.5.1.2.1. Development Services for Biopharmaceuticals
    - 10.5.1.2.2. Manufacturing Services for Biopharmaceuticals
  - 10.5.1.3. Manufacturing Facilities
  - 10.5.1.4. Recent Developments and Future Outlook
10.6. Biopharmaceutical Contract Manufacturing in Japan
- 10.6.1. Biopharmaceutical Contract Manufacturing in Japan: Regulatory Scenario
10.7. Leading Biopharmaceutical CMOs in Japan
- 10.7.1. Minaris Regenerative Medicine
  - 10.7.1.1. Company Overview
  - 10.7.1.2. Service Portfolio
    - 10.7.1.2.1. Manufacturing Development Services
    - 10.7.1.2.2. GMP Manufacturing
  - 10.7.1.3. Manufacturing Facilities
  - 10.7.1.4. Recent Developments and Future Outlook
10.8. Biopharmaceutical Contract Manufacturing in South Korea
- 10.8.1. Biopharmaceutical Contract Manufacturing in South Korea: Regulatory Scenario
10.9. Leading Biopharmaceutical CMOs in South Korea
- 10.9.1. Samsung Biologics
  - 10.9.1.1. Company Overview
  - 10.9.1.2. Service Portfolio
    - 10.9.1.2.1. Process Development
    - 10.9.1.2.2. Analytical Services
    - 10.9.1.2.3. cGMP Manufacturing Services
    - 10.9.1.2.4. Aseptic Fill / Finish Services
    - 10.9.1.2.5. Quality Services
  - 10.9.1.3. Financial Information
  - 10.9.1.4. Manufacturing Facilities
  - 10.9.1.5. Recent Developments and Future Outlook
10.10. Biopharmaceutical Contract Manufacturing in Australia
- 10.10.1. Biopharmaceutical Contract Manufacturing in Australia: Regulatory Scenario
10.11. Leading Biopharmaceutical CMOs in Australia
- 10.11.1. Cell Therapies
  - 10.11.1.1. Company Overview
  - 10.11.1.2. Service Portfolio
  - 10.11.1.3. Manufacturing Facilities
  - 10.11.1.4. Recent Developments and Future Outlook
10.12. Other Leading Biopharmaceutical CMOs in Asia-Pacific and Rest of the World
- 10.12.1 AcuraBio (Formerly Known as Luina Bio)
  - 10.12.1.1. Company Overview
- 10.12.2 Celltrion
  - 10.12.2.1. Company Overview
- 10.12.3 Takara Bio
  - 10.12.3.1. Company Overview

11. NICHE BIOPHARMACEUTICAL SECTORS

11.1. Chapter Overview
11.2. Bispecific Antibodies
- 11.2.1. Approved and Clinical Bispecific Antibody Therapeutics: Overall Market Landscape
- 11.2.2. Bispecific Antibodies: Pipeline Analysis
  - 11.2.2.1. Analysis by Phase of Development
  - 11.2.2.2. Analysis by Target Indication
- 11.2.3. Bispecific Antibody Therapeutics: Technology Platforms
- 11.2.4. Key Considerations for Manufacturing and Associated Challenges
- 11.2.5. Role of CMOs in Offering Services for Bispecific Antibodies
  - 11.2.5.1. CMOs Offering Services for Bispecific Antibodies
11.3. Antibody Drug Conjugates (ADCs)
- 11.3.1. Components of ADCs
  - 11.3.1.1. Antibody
  - 11.3.1.2. Cytotoxin
  - 11.3.1.3. Linker
- 11.3.2. Antibody Drug Conjugates (ADCs): Pipeline Analysis
  - 11.3.2.1. Analysis by Status of Development
  - 11.3.2.2. Analysis by Target Disease Indication
  - 11.3.2.3. Most Active Players: Analysis by Number of Therapies
- 11.3.3. Antibody Drug Conjugate Developers
- 11.3.4. Manufacturing Process
11.4. Cell Therapies
- 11.3.5. Technical Challenges Related to Antibody Drug Conjugates Manufacturing
- 11.3.6. Role of CMOs in Offering Services for ADCs
  - 11.3.6.1. CMOs Offering Services for ADCs
- 11.4.1. Cell Therapies: Overall Market Landscape
- 11.4.2. Overview of Cell Therapy Manufacturing
  - 11.4.2.1. Cell Therapy Manufacturing Models
    - 11.4.2.1.1. Centralized Manufacturing
    - 11.4.2.1.2. Decentralized Manufacturing
- 11.4.3. Key Challenges for Manufacturing Cell Therapies
- 11.4.4. Key Factors Impacting Cell Therapy Manufacturing
  - 11.4.4.1. Characterization
  - 11.4.4.2. Cost of Goods
  - 11.4.4.3. Automation of Cell Therapy Manufacturing
- 11.4.5 Cell Therapies: Pipeline Analysis
  - 11.4.5.1 Analysis by Type of Cell Manufactured
- 11.4.6. Stem Cell Therapies: Analysis by Phase of Development
- 11.4.7. T-Cell Therapies: Analysis by Phase of Development
- 11.4.8. Role of CMOs in Offering Services for Cell Therapies
  - 11.4.8.1. CMOs Offering Services for Cell Therapies
11.5. Gene Therapies
- 11.5.1. Gene Therapies: Pipeline Analysis
  - 11.5.1.1. Analysis by Stage of Development
  - 11.5.1.2. Analysis by Phase of Development
  - 11.5.1.3. Analysis by Type of Vector Used
    - 11.5.1.3.1. Clinical Pipeline
    - 11.5.1.3.2. Preclinical Pipeline
  - 11.5.1.4. Analysis by Therapeutic Area
    - 11.5.1.4.1. Clinical and Commercial Pipeline
    - 11.5.1.4.2. Preclinical Pipeline
- 11.5.2. Role of CMOs in Offering Services for Gene Therapies
  - 11.5.2.1. CMOs Offering Services for Gene Therapies
11.6. Viral Vectors
- 11.6.1. Viral Vectors: Pipeline Analysis
  - 11.6.1.1. Analysis by Location of Viral Vectors Manufacturing Facilities
  - 11.6.1.2. Analysis by Type of Viral Vector Manufactured
- 11.6.2. Role of CMOs in Offering Services for Viral Vectors
  - 11.6.2.1. CMOs Offering Services for Viral Vectors
11.7. Plasmid DNA
- 11.7.1. Plasmid DNA: Pipeline Analysis
  - 11.7.1.1. Analysis by Location of Manufacturing Facilities
- 11.7.2. Role of CMOs in Offering Services for Plasmid DNA
  - 11.7.2.1. CMOs Offering Services for Plasmid DNA

12. CASE STUDY: OUTSOURCING OF BIOSIMILARS

12.1. Chapter Overview
12.2. Overview of Biosimilars
12.3. Development Stages of Biosimilars
12.4. Regulatory Requirements for Licensing of Biosimilars
12.5. Need for Outsourcing Manufacturing Operations
12.6. Impact of Biosimilars on the Global Contract Manufacturing Market
- 12.6.1. Biosimilars: Historical Trend of FDA Approvals
12.7. Biosimilars Contract Manufacturing Service Providers
12.8. Challenges Associated with Outsourcing of Biosimilar Manufacturing Operations

13. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES

13.1. Chapter Overview
13.2. Small Molecule and Large Molecule Drugs / Therapies
- 13.2.1. Comparison of General Characteristics
- 13.2.2. Comparison of Key Specifications
- 13.2.3. Comparison of Manufacturing Process
- 13.2.4. Comparison of Key Manufacturing Challenges

14. CASE STUDY: IN-HOUSE MANUFACTURING

14.1. Chapter Overview
14.2. In-House Manufacturing
- 14.2.1. Benefits Associated with In-House Manufacturing
- 14.2.2. Risks Associated with In-House Manufacturing
14.3. Outsourcing Trends in the Biopharmaceutical Industry
- 14.3.1. Types of Outsourcing Partners
14.4. Manufacturing Approaches Used for Approved Biologics, 2016-2022
14.5. Choosing the Right Strategy: In-House Manufacturing versus Outsourcing

15. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

15.1. Chapter Overview
15.2. Key Assumptions and Parameters
15.3. Biopharmaceutical Contract Manufacturers: Make versus Buy Decision Making
- 15.3.1. Scenario 1
- 15.3.2. Scenario 2
- 15.3.3. Scenario 3
- 15.3.4. Scenario 4
15.4. Conclusion

16. BIG PHARMA INITIATIVES

16.1. Chapter Overview
16.2. Biopharmaceutical Related Initiatives by Big Pharmaceutical Players
- 16.2.1. Analysis by Number of Initiatives
- 16.2.2. Analysis by Year of Initiative
- 16.2.3. Analysis by Purpose of Initiative
- 16.2.4. Analysis by Type of Initiative
  - 16.2.4.1. Analysis by Type of Partnership
  - 16.2.4.2. Analysis by Type of Expansion
- 16.2.5. Analysis by Scale of Operation
- 16.2.6. Analysis by Type of Biologic Manufactured
- 16.2.7. Analysis of Big Pharma Players by Year of Initiative
- 16.2.8. Analysis of Big Pharma Players by Purpose of Initiative
- 16.2.9. Analysis by Year and Type of Initiative
- 16.2.10. Analysis of Big Pharma Players by Region of Expansion
- 16.2.11. Analysis of Big Pharma Players by Type of Biologic Manufactured

17. PARTNERSHIPS AND COLLABORATIONS

17.1. Chapter Overview
17.2. Partnership Models
17.3. Biopharmaceutical Contract Manufacturing: Partnerships and Collaborations
- 17.3.1. Analysis by Year of Partnership
- 17.3.2. Analysis by Type of Partnership
- 17.3.3. Analysis by Year and Type of Partnership
- 17.3.4. Analysis by Type of Biologic Manufactured
- 17.3.5. Analysis by Year of Partnership and Type of Biologic Manufactured
- 17.3.6. Analysis by Type of Partnership and Type of Biologic Manufactured
- 17.3.7. Analysis by Scale of Operation
- 17.3.8. Analysis by Therapeutic Area
- 17.3.9. Most Active Players: Analysis by Number of Partnerships
- 17.3.10. Analysis by Geography
  - 17.3.10.1. Local and International Agreements
  - 17.3.10.2. Intracontinental and Intercontinental Agreements

18. MERGERS AND ACQUISITIONS

18.1. Chapter Overview
18.2. Merger and Acquisition Models
18.3. Biopharmaceutical Contract Manufacturing: Mergers and Acquisitions
- 18.3.1. Cumulative Year-wise Trend of Mergers and Acquisitions
- 18.3.2. Analysis by Type of Acquisition
- 18.3.3. Analysis by Geography
  - 18.3.3.1. Local and International Mergers and Acquisitions
  - 18.3.3.2. Intracontinental and Intercontinental Mergers and Acquisitions
  - 18.3.3.3. Year-wise Trend in North America, Europe and Asia-Pacific
- 18.3.4. Most Active Acquirers: Analysis by Number of Acquisitions
- 18.3.5. Analysis by Key Value Drivers
- 18.3.6. Analysis by Year of Acquisition and Key Value Drivers
- 18.3.7. Analysis by Type of Biologic Manufactured
- 18.3.8. Analysis by Key Value Drivers and Type of Biologic Manufactured
18.4. Key Acquisitions: Deal Multiples
- 18.4.1. Year-wise Trend of Deal Multiple Amount

19. RECENT EXPANSIONS

19.1. Chapter Overview
19.2. Biopharmaceutical Contract Manufacturing: Recent Expansions
- 19.2.1. Analysis by Year of Expansion
- 19.2.2. Analysis by Purpose of Expansion
- 19.2.3. Analysis by Year and Purpose of Expansion
- 19.2.4. Analysis by Type of Biologic Manufactured
- 19.2.5. Analysis by Purpose of Expansion and Type of Biologic Manufactured
- 19.2.6. Analysis by Location of Expanded Facility
- 19.2.7. Most Active Players: Analysis by Number of Recent Expansions
- 19.2.8. Analysis by Purpose of Expansion and Location of Expanded Facility
- 19.2.9. Analysis by Amount Invested
- 19.2.10. Recent Expansions: 2016-2020 and 2021-2023 Scenario

20. RECENT DEVELOPMENTS

20.1. Chapter Overview
20.2. Types of Funding
20.3. Biopharmaceutical Contract Manufacturing: Funding and Investment Analysis
- 20.3.1. Analysis by Year of Funding
- 20.3.2. Analysis by Amount Invested
- 20.3.3. Analysis by Type of Funding
- 20.3.4. Analysis by Year and Type of Funding
- 20.3.5. Analysis of Funding Instances and Amount Invested by Geography (Continent)
- 20.3.6. Analysis of Funding Instances and Amount Invested by Geography (Country)
- 20.3.7. Most Active Players: Analysis by Number of Funding Instances
- 20.3.8. Most Active Players: Analysis by Total Amount Raised
- 20.3.9. Leading Investors: Analysis by Number of Funding Instances
- 20.3.10. Leading Investors: Analysis by Total Amount Raised
20.4. Technological Advancements
- 20.4.1. Single-Use Technology
- 20.4.2. Process Analytical Technology (PAT)
- 20.4.3. Continuous Processing
- 20.4.4. Quality by Design (QbD) in Bio-processing
- 20.4.5. Modular / Podular Biopharma Facilities

21. CAPACITY ANALYSIS

21.1. Chapter Overview
21.2. Key Assumptions and Methodology
21.3. Biopharmaceutical Contract Manufacturing: Global Installed Capacity
- 21.3.1. Analysis by Company Size
- 21.3.2. Analysis by Type of Expression System Used
- 21.3.3. Analysis by Geography
  - 21.3.3.1. Analysis of Biopharmaceutical Contract Manufacturing Capacity in North America
  - 21.3.3.2. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Europe
  - 21.3.3.3. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
  - 21.3.3.4. Analysis of Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
21.4. Concluding Remarks

22. DEMAND ANALYSIS

22.1. Chapter Overview
22.2. Key Assumptions and Methodology
22.3. Global Demand for Biopharmaceuticals
22.4. Global Demand for Emerging Novel Biologics
- 22.4.1. Global Demand for ADC Therapeutics
- 22.4.2. Global Demand for Cell Therapy Manufacturing

23. TOTAL COST OF OWNERSHIP FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS

23.1. Chapter Overview
23.2. Key Parameters
23.3. Assumptions and Methodology
23.4. Total Cost of Ownership (Sample Dataset)
23.5. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
- 23.5.1. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0
- 23.5.2. Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20
23.7. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20
- 23.7.1. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by CAPEX, Y0
- 23.7.2. Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations: Analysis by OPEX, Y1-Y20

24. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET

24.1. Chapter Overview
24.2. Assumptions and Methodology
24.3. Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 24.3.1. Scenario Analysis
  - 24.3.1.1. Conservative Scenario
  - 24.3.1.2. Optimistic Scenario
24.4. Key Market Segmentations

25. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF SERVICE OFFERED

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, Current Year and 2035
- 25.3.1. API Manufacturing: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 25.3.2. FDF Manufacturing: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
25.4. Data Triangulation and Validation

26. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, Current Year and 2035
- 26.3.1. Antibodies: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 26.3.2. Cell Therapies: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 26.3.3. Vaccines: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 26.3.4. Other Biologics: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
26.4. Data Triangulation and Validation

27. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, Current Year and 2035
- 27.3.1. Mammalian Expression Systems: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 27.3.2. Microbial Expression Systems: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 27.3.3. Other Expression Systems: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
27.4. Data Triangulation and Validation

28. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, Current Year and 2035
- 28.3.1. Preclinical / Clinical Operations: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 28.3.2. Commercial Operations: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
28.4. Data Triangulation and Validation

29. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE

29.1. Chapter Overview
29.2. Key Assumptions and Methodology
29.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, Current Year and 2035
- 29.3.1. Small Companies: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 29.3.2. Mid-sized Companies: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 29.3.3. Large and Very Large Companies: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
29.4. Data Triangulation and Validation

30. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY

30.1. Chapter Overview
30.2. Key Assumptions and Methodology
30.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Geography, 2018, 2023 and 2035
- 30.3.1. North America: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.1.1. US: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.1.2. Canada: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 30.3.2. Europe: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.2.1. Italy: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.2.2. Germany: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.2.3. France: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.2.4. Spain: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.2.5. UK: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.2.6. Rest of Europe: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 30.3.3. Asia-Pacific: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.3.1. China: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.3.2. India: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.3.3. South Korea: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.3.4. Japan: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
  - 30.3.3.5. Rest of Asia-Pacific: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 30.3.4. Latin America: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
- 30.3.5. Middle East and North Africa: Historical Trends (Since 2018) and Forecasted Estimates (till 2035)
30.4. Data Triangulation and Validation

31. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY LEADING PLAYERS

31.1. Chapter Overview
31.2. Key Assumptions and Methodology
31.3. Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players
31.4. Data Triangulation and Validation

32. CASE STUDY: VIRTUAL PHARMACEUTICAL COMPANIES

32.1. Chapter Overview
32.2. Historical Evolution of the Virtual Business Model
32.3. Virtual Pharmaceutical Companies as a Subset of the Overall Biopharmaceutical Industry
32.4. Advantages Associated with Outsourcing Operations to Virtual Service Providers
32.5. Key Challenges Associated with Outsourcing Operations to Virtual Service Providers

33. SWOT ANALYSIS

33.1. Chapter Overview
33.2. Strengths
33.3. Weaknesses
33.4. Opportunities
33.5. Threats
33.6. Comparison of SWOT Factors
33.7. Conclusion

34. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

34.1. Chapter Overview
34.2. Outsourcing Activities to Witness Significant Growth in the Coming Years
34.3. Shift from One-time Contracts to Strategic Partnerships
34.4. Integration / Adoption of New and Innovative Technologies
- 34.4.1. Single-use Bioreactors
- 34.4.2. Novel Bioprocess Techniques
- 34.4.3. Bioprocess Automation
34.5. Focus on Niche Therapeutic Areas
34.6. Growing Biosimilars Market to Contribute to the Growth of the Contract Services Segment
34.7. Capability Expansion by CMOs to become One-Stop-Shops
34.8. Offshoring Outsourcing Activities to Maximize Profits and Expand Existing Capacities
34.9. Increase in Financial Inflow and Outsourcing Budgets
34.10. Challenges Faced by Sponsors and Service Providers
- 34.10.1. Concerns Related to Single-use Systems
- 34.10.2. Issues Related to Capacity Fluctuations
34.11. Concluding Remarks

35. CONCLUSION

36. EXECUTIVE INSIGHTS

36.1. Chapter Overview
36.2. RoslinCT
- 36.2.1. Company Snapshot
- 36.2.2. Interview Transcript: Peter Coleman, Chief Executive Officer
36.3. JAFRAL Biosolutions
- 36.3.1. Company Snapshot
- 36.3.2. Interview Transcript: Frenk Smrekar, Chief Executive Officer And Co-Founder
36.4. Discovery Life Sciences
- 36.4.1. Company Snapshot
- 36.4.2. Interview Transcript: Dominic Clarke, Chief Technical Officer, Cell And Gene Therapy
36.5. Bioworkshops
- 36.5.1. Company Snapshot
- 36.5.2. Interview Transcript: Nick Kotlarski, President and Chief Operating Officer
36.6. Aldevron
- 36.6.1. Company Snapshot
- 36.6.2. Interview Transcript: Jeff Briganti, Senior Director Of Global Strategic Marketing
36.7. Resilience
- 36.7.1. Company Snapshot
- 36.7.2. Interview Transcript: Tarek Abdel-Gawad, Senior Director of Commercial Strategy and Market Insights
36.8. Minaris Regenerative Medicine
- 36.8.1. Company Snapshot
- 36.8.2. Interview Transcript: Luc St-Onge, Global Head of Sales and Marketing and Head of Business Development (Germany)
36.9. 53Biologics
- 36.9.1. Company Snapshot
- 36.9.2. Interview Transcript: Francisco Manuel Reyes Sosa, Business Development Manager
36.10. Richter-Helm BioLogics
- 36.10.1. Company Snapshot
- 36.10.2. Interview Transcript Antje Weingarth, Manager Marketing and Sales

37. APPENDIX I: TABULATED DATA

38. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

39. APPENDIX III: DETAILS OF PARTNERSHIPS AND COLLABORATIONS

Product Code: RA100465

List of Tables

Table 5.1 Mammalian versus Microbial Expression Systems
Table 6.1 List of Biopharmaceutical Contract Manufacturers
Table 6.2 Biopharmaceutical Contract Manufacturers: Information on Type of Service Offered
Table 6.3 Biopharmaceutical Contract Manufacturers: Information on Type of Biologic Manufactured
Table 6.6 Biopharmaceutical Contract Manufacturers: Information on Scale of Operation
Table 6.5 Biopharmaceutical Contract Manufacturers: Information on Type of Expression System Used
Table 6.6 Biopharmaceutical Contract Manufacturers: Information on Type of Bioreactor Used
Table 6.7 Biopharmaceutical Contract Manufacturers: Information on Mode of Operation of Bioreactor
Table 7.1 List of Biopharmaceutical Contract Manufacturing Facilities in North America
Table 7.2 List of Biopharmaceutical Contract Manufacturing Facilities in Europe
Table 7.3 List of Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Table 7.4 List of Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Table 8.1 AGC Biologics: Company Overview
Table 8.2 AGC Biologics: Biologics Manufacturing Facilities
Table 8.3 AGC Biologics: Recent Developments and Future Outlook
Table 8.4 Catalent: Company Overview
Table 8.5 Catalent: Biologics Manufacturing Facilities
Table 8.6 Catalent: Recent Developments and Future Outlook
Table 8.7 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 8.8 FUJIFILM Diosynth Biotechnologies: Biologics Manufacturing Facilities
Table 8.9 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
Table 8.10 KBI Biopharma: Company Overview
Table 8.11 KBI Biopharma: Biologics Manufacturing Facilities
Table 8.12 KBI Biopharma: Recent Developments and Future Outlook
Table 8.13 Charles River Laboratories: Company Overview
Table 8.14 Charles River Laboratories: Biologics Manufacturing Facilities
Table 8.15 Charles River Laboratories: Recent Developments and Future Outlook
Table 8.16 Cytiva: Company Overview
Table 8.17 Patheon: Company Overview
Table 8.18 Piramal Pharma Solutions: Company Overview
Table 9.1 FDA Quality Agreements and EMA cGMP Regulations: A Comparative Analysis
Table 9.2 Boehringer Ingelheim: Company Overview
Table 9.3 Boehringer Ingelheim: Biologics Manufacturing Facilities
Table 9.4 Boehringer Ingelheim: Recent Developments and Future Outlook
Table 9.5 Lonza: Company Overview
Table 9.6 Lonza: Biologics Manufacturing Facilities
Table 9.7 Lonza: Recent Developments and Future Outlook
Table 9.8 Sandoz: Company Overview
Table 9.9 Sandoz: Biologics Manufacturing Facilities
Table 9.10 Sandoz: Recent Developments and Future Outlook
Table 9.11 Vetter Pharma: Company Overview
Table 9.12 Vetter Pharma: Biologics Manufacturing Facilities
Table 9.13 Vetter Pharma: Recent Developments and Future Outlook
Table 9.14 Miltenyi Biotec: Company Overview
Table 9.15 Miltenyi Biotec: Biologics Manufacturing Facilities
Table 9.16 Miltenyi Biotec: Recent Developments and Future Outlook
Table 9.17 Novasep: Company Overview
Table 9.18 Olon: Company Overview
Table 9.19 Rentschler Biopharma: Company Overview
Table 10.1 WuXi Biologics: Company Overview
Table 10.2 Wuxi Biologics: Biologics Manufacturing Facilities
Table 10.3 WuXi Biologics: Recent Developments and Future Outlook
Table 10.4 Kemwell Biopharma: Company Overview
Table 10.5 Kemwell Biopharma: Recent Developments and Future Outlook
Table 10.6 Minaris Regenerative Medicine: Company Overview
Table 10.7 Minaris Regenerative Medicine: BiologicsManufacturing Facilities
Table 10.8 Minaris Regenerative Medicine: Recent Developments and Future Outlook
Table 10.9 Samsung BioLogics: Company Overview
Table 10.10 Samsung BioLogics: Biologics Manufacturing Facilities
Table 10.11 Samsung BioLogics: Recent Developments and Future Outlook
Table 10.12 Cell Therapies: Company Overview
Table 10.13 Cell Therapies: Recent Developments and Future Outlook
Table 10.14 AcuraBio: Company Overview
Table 10.15 Celltrion: Company Overview
Table 10.16 Takara Bio: Company Overview
Table 11.1 Bispecific Antibody Therapeutics: Information on Drug Candidate, Developer, Phase of Development and Target Antigen
Table 11.2 Bispecific Antibody Therapeutics: Information on Clinical Drug Candidates, Target Indications, Therapeutic Areas and Disease Segment
Table 11.3 Bispecific Antibody Therapeutics: List of Technology Platforms
Table 11.4 Bispecific Antibody Contract Manufacturers: List of Companies
Table 11.5 Commonly Used Cytotoxins for ADC Therapeutics
Table 11.6 Occupational Exposure Limit Bands, Safebridge Consultants
Table 11.7 Antibody Drug Conjugates: Information on Drug Candidates, Developers, Status of Development, Target Disease Indications and Therapeutic Areas
Table 11.8 Antibody Drug Conjugate Developers: Information on Year of Establishment, Company Size and Location of Headquarters
Table 11.9 ADC Contract Manufacturers: List of Companies
Table 11.10 Cell-based Therapies: Applications
Table 11.11 Cell-based Therapies: Commercialized Products,
Table 11.12 Key Cell Therapy Manufacturing Steps
Table 11.13 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 11.14 Cell Therapy Manufacturing (Industry Players): Information on Type of Cell Manufactured
Table 11.15 Cell Therapy Contract Manufacturers: List of Companies
Table 11.16 Gene Therapy Contract Manufacturers: List of Companies
Table 11.17 Vector and Gene Therapy Manufacturers (Non-Industry players): Information on Type of Vector Manufactured
Table 11.18 Viral Vectors Contract Manufacturers: List of Companies
Table 11.19 Plasmid DNA Manufacturing Service Providers: Information on Location of Manufacturing Facility
Table 11.20 Plasmid DNA Contract Manufacturers: List of Companies
Table 12.1 List of Biosimilars Contract Manufacturing Service Providers
Table 13.1 Small Molecules and Large Molecules: Strengths and Weaknesses
Table 13.2 Small Molecules and Large Molecules: Comparison of Key Characteristics
Table 13.3 Small Molecules and Large Molecules: Comparison of Development Characteristics
Table 14.1 List of FDA Approved Biologics (2016-2022)
Table 16.1 Big Pharma Initiatives: List of Biopharmaceutical Manufacturing Initiatives
Table 17.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations, Since 2019
Table 17.2 Partnerships and Collaborations: Information on Type of Biologic Manufactured
Table 18.1 Biopharmaceutical Contract Manufacturing: List of Mergers and Acquisitions, Since 2015
Table 18.2 Mergers and Acquisitions: Information on Key Value Drivers and Type of Biologic Manufactured
Table 18.3 Mergers and Acquisitions: Information on Deal Multiples, Since 2015
Table 19.1 Biopharmaceutical Contract Manufacturing: List of Recent Expansions, Since 2016
Table 20.1 Biopharmaceutical Contract Manufacturing: List of Funding and Investments, Since 2016
Table 20.2 Funding and Investment Analysis: Summary of Investments
Table 20.3 Funding and Investment Analysis: Summary of Venture Capital Funding
Table 21.1 Biopharmaceutical Contract Manufacturers: Information on Capacity (Sample Data Set)
Table 21.2 Capacity Analysis: Average Capacity per Category (Sample Data Set)
Table 21.3 Capacity Analysis: Average Capacity for Mammalian Expression Systems (Sample Data Set)
Table 21.4 Capacity Analysis: Average Capacity for Microbial Expression Systems (Sample Data Set)
Table 21.5 Capacity Analysis: Average Capacity for Other Expression Systems (Sample Data Set)
Table 21.6 Capacity Analysis: Global Production Capacity
Table 22.1 Annual Biomanufacturing Capacity, till 2035 (Million Liters)
Table 23.1 Total Cost of Ownership: Sample Dataset for Mid-sized Companies
Table 23.2 Total Cost of Ownership: Sample Dataset for Large / Very Large Companies
Table 31.1 List of Leading Biopharmaceutical Contract Manufacturing Companies
Table 32.1 List of Virtual Biopharmaceutical Companies
Table 36.1 RoslinCT: Key Highlights
Table 36.2 Jafral Biosolutions: Key Highlights
Table 36.3 Discovery Life Sciences: Key Highlights
Table 36.4 Bioworkshops: Key Highlights
Table 36.5 Aldevron: Key Highlights
Table 36.6 Resilience: Key Highlights
Table 36.7 Minaris Regenerative Medicine: Key Highlights
Table 36.8 53Biologics: Key Highlights
Table 36.9 Richter-Helm BioLogics: Key Highlights
Table 37.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Table 37.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Table 37.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)
Table 37.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Table 37.5 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region)
Table 37.6 Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Table 37.7 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Table 37.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters (Region)
Table 37.9 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Company Size
Table 37.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Table 37.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Table 37.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Table 37.13 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used and Location of Headquarters (Region)
Table 37.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Table 37.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Table 37.16 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Table 37.17 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered
Table 37.18 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Table 37.19 AGC Biologics: Annual Revenues, FY 2018 Onwards(JPY Billion)
Table 37.20 Catalent: Annual Revenues, FY 2018 Onwards (USD Billion)
Table 37.21 FUJIFILM Diosynth Biotechnologies: Annual Revenues, FY 2018 Onwards(JPY Billion)
Table 37.22 FUJIFILM Holdings: Annual Revenues by Business Divisions Current Year(JPY Billion)
Table 37.23 Charles River Laboratories: Annual Revenues, FY 2018 Onwards (USD Billion)
Table 37.24 Boehringer Ingelheim: Annual Revenues, FY 2018 Onwards (EUR Billion)
Table 37.25 Lonza: Annual Revenues, FY 2018 Onwards (CHF Billion)
Table 37.26 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Table 37.27 Sandoz: Annual Revenues, FY 2018 Onwards(USD Billion)
Table 37.28 Wuxi Biologics: Annual Revenues, FY 2018Onwards (RMB Billion)
Table 37.29 Samsung Biologics: Annual Revenues, FY 2018 Onwards (KRW Billion)
Table 37.30 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Table 37.31 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indications
Table 37.32 Antibody Drug Conjugates: Distribution by Status of Development
Table 37.33 Antibody Drug Conjugates: Distribution by Target Disease Indication
Table 37.34 Most Active Players: Distribution by Number of Therapies
Table 37.35 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Table 37.36 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Table 37.37 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Table 37.38 Stem Cell Therapies: Distribution by Phase of Development
Table 37.39 T-Cell Therapies: Distribution by Phase of Development
Table 37.40 Gene Therapies: Distribution by Stage of Development
Table 37.41 Gene Therapies: Distribution by Phase of Development
Table 37.42 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 37.43 Early-stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Table 37.44 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 37.45 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Table 37.46 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent)
Table 37.47 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Table 37.48 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Table 37.49 Biosimilars: Historical Trend of FDA Approval, 2015-2022
Table 37.50 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022
Table 37.51 Big Pharma Initiatives: Distribution of Players by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives
Table 37.52 Big Pharma Initiatives: Cumulative Year-wise Trend, Since 2005
Table 37.53 Big Pharma Initiatives: Distribution by Purpose of Initiative
Table 37.54 Big Pharma Initiatives: Distribution by Type of Initiative
Table 37.55 Big Pharma Initiatives: Distribution by Type of Partnership
Table 37.56 Big Pharma Initiatives: Distribution by Type of Expansion
Table 37.57 Big Pharma Initiatives: Distribution by Scale of Operation
Table 37.58 Big Pharma Initiatives: Distribution by Type of Biologic Manufactured
Table 37.59 Big Pharma Initiatives: Distribution of Players by Purpose of Initiative
Table 37.60 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Table 37.61 Big Pharma Initiatives: Distribution of Players by Region of Expansion
Table 37.62 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
Table 37.63 Partnerships and Collaborations: Distribution by Type of Partnership
Table 37.64 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 37.65 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Table 37.66 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Table 37.67 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured and Geography
Table 37.68 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured
Table 37.69 Partnerships and Collaborations: Distribution by Scale of Operation
Table 37.70 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 37.71 Most Active Players: Distribution by Number of Partnerships
Table 37.72 Partnerships and Collaborations: Local and International Agreements
Table 37.73 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Table 37.74 Mergers and Acquisitions: Year-Wise Cumulative Trend, Since 2015
Table 37.75 Mergers and Acquisitions: Distribution by Type of Agreement
Table 37.76 Mergers and Acquisitions: Intracontinental and Intercontinental Agreements
Table 37.77 Mergers and Acquisitions: Local and International Agreements
Table 37.78 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific, Since 2015
Table 37.79 Most Active Acquirers: Distribution by Number of Acquisitions
Table 37.80 Mergers and Acquisitions: Distribution by Key Value Drivers
Table 37.81 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Table 37.82 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Table 37.83 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Table 37.84 Mergers and Acquisitions: Year-Wise Trend of Deal Multiple Amount (USD Million)
Table 37.85 Recent Expansions: Cumulative Year-wise Trend, Since 2016
Table 37.86 Recent Expansions: Distribution by Purpose of Expansion
Table 37.87 Recent Expansions: Distribution by Year and Purpose of Expansion
Table 37.88 Recent Expansions: Distribution by Type of Biologic Manufactured
Table 37.89 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Table 37.90 Recent Expansions: Distribution by Location of Expanded Facility
Table 37.91 Most Active Players: Distribution by Number of Recent Expansions
Table 37.92 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
Table 37.93 Recent Expansions: Distribution by Amount Invested (USD Million)
Table 37.94 Funding and Investment Analysis: Cumulative Year-wise Trend of Number of Funding Instances, Since 2016
Table 37.95 Funding and Investment Analysis: Cumulative Year-wise Trend of Total Amount Invested, Since 2016 (USD Million)
Table 37.96 Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding
Table 37.97 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding (USD Million)
Table 37.98 Funding and Investment Analysis: Distribution by Year and Type of Funding
Table 37.99 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Continent) (USD Million)
Table 37.100 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Country) (USD Million)
Table 37.101 Most Active Players: Distribution by Number of Funding Instances
Table 37.102 Most Active Players: Distribution by Total Amount Raised (USD Million)
Table 37.103 Leading Investors: Distribution by Number of Funding Instances
Table 37.104 Leading Investors: Distribution by Total Amount Invested (USD Million)
Table 37.105 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Company Size
Table 37.106 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Type of Expression System Used
Table 37.107 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Location of Manufacturing Facilities
Table 37.108 Biopharmaceutical Contract Manufacturing Capacity in North America
Table 37.109 Biopharmaceutical Contract Manufacturing Capacity in Europe
Table 37.110 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific
Table 37.111 Capacity Analysis: Biopharmaceutical Contract Manufacturing Capacity in Rest of the World
Table 37.112 Global Demand for Biopharmaceuticals, 2023-2235 (in kilograms)
Table 37.113 Global Demand for ADC Therapeutics, till 2035 (in kilograms)
Table 37.114 Global Demand for Cell Therapies, till 2035 (in terms of Number of Patients)
Table 37.115 Global Demand for Cell Therapies, till 2035 (Billion Cells)
Table 37.116 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 37.117 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 37.118 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 37.119 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Table 37.120 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Table 37.121 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 37.122 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.123 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, Current Year and 2035 (USD Billion)
Table 37.124 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.125 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.126 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, Current Year and 2035 (USD Billion)
Table 37.127 Biopharmaceutical Contract Manufacturing Market for Antibodies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.128 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.129 Biopharmaceutical Contract Manufacturing Market for Vaccines, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.130 Biopharmaceutical Contract Manufacturing Market for Other Biologics, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.131 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, Current Year and 2035 (USD Billion)
Table 37.132 Biopharmaceutical Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.133 Biopharmaceutical Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.134 Biopharmaceutical Contract Manufacturing Market for Other Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.135 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, Current Year and 2035 (USD Billion)
Table 37.136 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.137 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.138 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, Current Year and 2035 (USD Billion)
Table 37.139 Biopharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.140 Biopharmaceutical Contract Manufacturing Market for Mid-sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (till2035) (USD Billion)
Table 37.141 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.142 Biopharmaceutical Contract Manufacturing Market: Distribution by Key Geographical Regions, 2018, Current Year and 2035 (USD Billion)
Table 37.143 Biopharmaceutical Contract Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.144 Biopharmaceutical Contract Manufacturing Market in the US, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.145 Biopharmaceutical Contract Manufacturing Market in Canada, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.146 Biopharmaceutical Contract Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.147 Biopharmaceutical Contract Manufacturing Market in Italy, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.148 Biopharmaceutical Contract Manufacturing Market in Germany, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.149 Biopharmaceutical Contract Manufacturing Market in France, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.150 Biopharmaceutical Contract Manufacturing Market in Spain, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.151 Biopharmaceutical Contract Manufacturing Market in the UK, Historical Trends(Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.152 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.153 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.154 Biopharmaceutical Contract Manufacturing Market in China, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.155 Biopharmaceutical Contract Manufacturing Market in India, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.156 Biopharmaceutical Contract Manufacturing Market in South Korea, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.157 Biopharmaceutical Contract Manufacturing Market in Japan, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.158 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.159 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.160 Biopharmaceutical Contract Manufacturing Market in Latin America, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Table 37.161 Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players (USD Billion)
Table 31.162 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market (USD Billion)
Table 37.163 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year
Table 39.1 Biopharmaceutical Contract Manufacturing: List of Partnerships and Collaborations

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentation
Figure 3.1 Lessons Learnt from Past Recessions
Figure 4.1 Executive Summary: Overall Market Landscape
Figure 4.2 Executive Summary: Regional Capability Analysis
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Mergers and Acquisitions
Figure 4.5 Executive Summary: Recent Expansions
Figure 4.6 Executive Summary: Funding and Investment Analysis
Figure 4.7 Executive Summary: Demand Analysis
Figure 4.8 Executive Summary: Total Cost of Ownership
Figure 4.9 Executive Summary: Market Forecast and Opportunity Analysis
Figure 5.1 Types of Biopharmaceuticals
Figure 5.2 Types of Expression Systems Used for the Production of Biopharmaceuticals
Figure 5.3 Stages of the Biomanufacturing Process
Figure 5.4 Types of Third-Party Service Providers
Figure 5.5 Commonly Outsourced Biopharmaceutical Contract Manufacturing Operations
Figure 6.1 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment
Figure 6.2 Biopharmaceutical Contract Manufacturers: Distribution by Company Size
Figure 6.3 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Region)
Figure 6.4 Biopharmaceutical Contract Manufacturers: Distribution by Location of Headquarters (Country)
Figure 6.5 Biopharmaceutical Contract Manufacturers: Distribution by Year of Establishment, Company Size and Location of Headquarters (Region)
Figure 6.6 Biopharmaceutical Contract Manufacturers: Distribution by Type of Service Offered
Figure 6.7 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured
Figure 6.8 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Location of Headquarters (Region)
Figure 6.9 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Company Size
Figure 6.10 Biopharmaceutical Contract Manufacturers: Distribution by Scale of Operation
Figure 6.11 Biopharmaceutical Contract Manufacturers: Distribution by Type of Biologic Manufactured and Scale of Operation
Figure 6.12 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used
Figure 6.13 Biopharmaceutical Contract Manufacturers: Distribution by Type of Expression System Used and Location of Headquarters (Region)
Figure 6.14 Biopharmaceutical Contract Manufacturers: Distribution by Type of Bioreactor Used
Figure 6.15 Biopharmaceutical Contract Manufacturers: Distribution by Mode of Operation of Bioreactor
Figure 7.1 Regional Distribution of Biopharmaceutical Contract Manufacturing Facilities
Figure 7.2 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Type of Service Offered
Figure 7.3 Biopharmaceutical Contract Manufacturing Facilities: Distribution by Scale of Operation
Figure 7.4 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in North America
Figure 7.5 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Europe
Figure 7.6 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Asia-Pacific
Figure 7.7 Regional Capability Analysis: Biopharmaceutical Contract Manufacturing Facilities in Rest of the World
Figure 8.1 Biopharmaceutical Contract Manufacturing Industry: The US Market Scenario
Figure 8.2 Biopharmaceutical Contract Manufacturing in the US: Growth Drivers and Challenges
Figure 8.3 US FDA Guidelines: Elements of a Quality Agreement
Figure 8.4 US FDA Guidelines: Key Considerations for Biologic Manufacturing Operations
Figure 8.5 AGC Biologics: Annual Revenues, Since FY 2018 (JPY Billion)
Figure 8.6 Catalent: Service Portfolio
Figure 8.7 Catalent: Biosimilars Service Portfolio
Figure 8.8 Catalent: Annual Revenues, Since FY-2018 (USD Billion)
Figure 8.9 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 8.10 FUJIFILM Diosynth Biotechnologies: Annual Revenues, Since FY 2018 (JPY Billion)
Figure 8.11 FUJIFILM Holdings: Annual Revenues by Business Divisions, Current Year (JPY Billion)
Figure 8.12 KBI Biopharma: Service Portfolio
Figure 8.13 Charles River Laboratories: Service Portfolio
Figure 8.14 Charles River Laboratories: Annual Revenues, Since FY 2018 (USD Billion)
Figure 9.1 Biopharmaceutical Contract Manufacturing in Europe: Growth Drivers and Challenges
Figure 9.2 EMA GMP Guidelines: Key Considerations for the Contract Giver, Contract Acceptor and the Contract
Figure 9.3 Boehringer Ingelheim (BioXcellenece): Service Portfolio
Figure 9.4 Boehringer Ingelheim: Annual Revenues, Since FY 2018 (EUR Billion)
Figure 9.5 Lonza: Service Portfolio
Figure 9.6 Lonza: Annual Revenues, Since FY 2018 (CHF Billion)
Figure 9.7 Lonza: Annual Revenues by Business Divisions (CHF Billion)
Figure 9.8 Sandoz: Annual Revenues, Since FY 2018 (USD Billion)
Figure 9.9 Vetter Pharma: Service Portfolio
Figure 10.1 Chinese Regulatory Guidelines: Key Considerations for the Contract Giver
Figure 10.2 Chinese Regulatory Guidelines: Key Considerations for the Contract Acceptor
Figure 10.3 Chinese Regulatory Guidelines: Key Aspects of the Contract
Figure 10.4 WuXi Biologics: Service Portfolio
Figure 10.5 Wuxi Biologics: Annual Revenues, Since FY 2018 (RMB Billion)
Figure 10.6 Biopharmaceutical Contract Manufacturing in India: Growth Drivers
Figure 10.7 Kemwell Biopharma: Service Portfolio
Figure 10.8 Minaris Regenerative Medicine: Service Portfolio
Figure 10.9 Samsung Biologics: Service Portfolio
Figure 10.10 Samsung Biologics: Annual Revenues, Since FY 2018 (KRW Billion)
Figure 10.11 Cell Therapies: Service Portfolio
Figure 11.1 Basic Structure of an Antibody
Figure 11.2 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Phase of Development
Figure 11.3 Approved and Clinical Bispecific Antibody Therapeutics: Distribution by Target Indication
Figure 11.4 Structure of an Antibody Drug Conjugate (ADC)
Figure 11.5 Antibody Drug Conjugates: Distribution by Status of Development
Figure 11.6 Antibody Drug Conjugates: Distribution by Target Disease Indication
Figure 11.7 Most Active Players: Distribution by Number of Therapies
Figure 11.8 Decentralized Manufacturing: Process Model
Figure 11.9 Cell Therapies: Challenges and Drivers
Figure 11.10 Cell Therapies: Potency as Critical Quality Attribute
Figure 11.11 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Cell Manufactured
Figure 11.12 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Immune Cell Manufactured
Figure 11.13 Cell Therapy Manufacturing (Industry Players): Distribution by Type of Stem Cell Manufactured
Figure 11.14 Stem Cell Therapies: Distribution by Phase of Development
Figure 11.15 T-Cell Therapies: Distribution by Phase of Development
Figure 11.16 Gene Therapies: Distribution by Stage of Development
Figure 11.17 Gene Therapies: Distribution by Phase of Development
Figure 11.18 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Type of Vector Used
Figure 11.19 Early-stage Pipeline of Gene Therapies: Distribution by Type of Vector Used
Figure 11.20 Clinical and Commercial Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 11.21 Early-Stage Pipeline of Gene Therapies: Distribution by Therapeutic Area
Figure 11.22 Viral Vector and Gene Therapy Manufacturers (Industry Players): Distribution by Location of Viral Vector Manufacturing Facilities (Continent-wise)
Figure 11.23 Vector and Gene Therapy Manufacturers (Non-Industry Players): Distribution by Type of Vector Manufactured
Figure 11.24 Plasmid DNA Manufacturers: Distribution by Location of Manufacturing Facility
Figure 12.1 Manufacturing Stages of a Biosimilar Product
Figure 12.2 Analytical and Functional Characterization Methods for Key Biosimilar Product
Figure 12.3 Regulatory Process Adopted for Licensing of a Biosimilar Product
Figure 12.4 Need for Outsourcing Biosimilar Manufacturing Operations
Figure 12.5 Biosimilars: Historical Trend of FDA Approvals, Since 2015
Figure 12.6 Challenges Associated with Outsourcing Biosimilar Manufacturing Operations
Figure 13.1 Small Molecule and Large Molecule Drugs: Historical Trend of FDA Approval, 2005-2022
Figure 13.2 Small Molecules versus Large Molecules: Comparison of Manufacturing Process
Figure 14.1 Benefits Associated with In- House Manufacturing
Figure 14.2 Risks Associated with In-House Manufacturing
Figure 14.3 Advantages and Disadvantages of Different Types of Outsourcing Partnerships
Figure 15.1 Make versus Buy Decision Making Framework
Figure 15.2 Make versus Buy Decision Making Framework: Possible Scenarios
Figure 16.1 Big Pharma Initiatives: Distribution of Players by Number of Biopharmaceutical Contract Manufacturing Focused Initiatives
Figure 16.2 Big Pharma Initiatives: Cumulative Year-wise Trend, Since 2005
Figure 16.3 Big Pharma Initiatives: Distribution by Purpose of Initiative
Figure 16.4 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 16.5 Big Pharma Initiatives: Distribution by Type of Partnership
Figure 16.6 Big Pharma Initiatives: Distribution by Type of Expansion
Figure 16.7 Big Pharma Initiatives: Distribution by Scale of Operation
Figure 16.8 Big Pharma Initiatives: Distribution by Type of Biologic Manufactured
Figure 16.9 Big Pharma Initiatives: Distribution of Players by Year and Number of Initiatives
Figure 16.10 Big Pharma Initiatives: Distribution of Players by Purpose of Initiative
Figure 16.11 Big Pharma Initiatives: Distribution by Year and Type of Initiative
Figure 16.12 Big Pharma Initiatives: Distribution of Players by Region of Expansion
Figure 16.13 Big Pharma Initiatives: Distribution of Players by Type of Biologic Manufactured
Figure 17.1 Partnerships and Collaborations: Cumulative Year-wise Trend, Since 2019
Figure 17.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 17.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 17.4 Partnerships and Collaborations: Distribution by Type of Biologic Manufactured
Figure 17.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Biologic Manufactured
Figure 17.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Biologic Manufactured
Figure 17.7 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 17.8 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 17.9 Most Active Players: Distribution by Number of Partnerships
Figure 17.10 Partnerships and Collaborations: Local and International Agreements
Figure 17.11 Partnerships and Collaborations: Intracontinental and Intercontinental Agreements
Figure 18.1 Mergers and Acquisitions: Year-Wise Cumulative Trend, Since 2015
Figure 18.2 Mergers and Acquisitions: Distribution by Type of Acquisition
Figure 18.3 Local and International Mergers and Acquisitions
Figure 18.4 Intracontinental and Intercontinental Mergers and Acquisitions
Figure 18.5 Mergers and Acquisitions: Year-Wise Trend in North America, Europe and Asia-Pacific, Since 2015
Figure 18.6 Most Active Acquirers: Distribution by Number of Acquisitions
Figure 18.7 Catalent Biologics: Information on Key Acquisitions
Figure 18.8 Mergers and Acquisitions: Distribution by Key Value Drivers
Figure 18.9 Mergers and Acquisitions: Distribution by Year of Acquisition and Key Value Drivers
Figure 18.10 Mergers and Acquisitions: Distribution by Type of Biologic Manufactured
Figure 18.11 Mergers and Acquisitions: Distribution by Key Value Drivers and Type of Biologic Manufactured
Figure 18.12 Mergers and Acquisitions: Year-Wise Trend of Deal Multiple Amount (USD Million)
Figure 19.1 Recent Expansions: Cumulative Year-wise Trend, Since 2016
Figure 19.2 Recent Expansions: Distribution by Purpose of Expansion
Figure 19.3 Recent Expansions: Distribution by Year and Purpose of Expansion
Figure 19.4 Recent Expansions: Distribution by Type of Biologic Manufactured
Figure 19.5 Recent Expansions: Distribution by Purpose of Expansion and Type of Biologic Manufactured
Figure 19.6 Recent Expansions: Distribution by Location of Expanded Facility
Figure 19.7 Most Active Players: Distribution by Number of Recent Expansions
Figure 19.8 Recent Expansions: Distribution by Purpose of Expansion and Location of Expanded Facility
Figure 19.9 Recent Expansions: Distribution by Amount Invested (USD Million)
Figure 19.10 Recent Expansions: Regional Comparison 2016-2020 and 2021-2023 Scenario
Figure 20.1 Funding and Investment Analysis: Cumulative Year- wise Trend, Since 2016
Figure 20.2 Funding and Investment Analysis: Cumulative Year- wise Trend by Amount Invested, Since 2016 (USD Million)
Figure 20.3 Funding and Investment Analysis: Distribution of Funding Instances by Type of Funding
Figure 20.4 Funding and Investment Analysis: Distribution of Amount Invested by Type of Funding (USD Million)
Figure 20.5 Funding and Investment Analysis: Distribution by Year and Type of Funding
Figure 20.6 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Continent) (USD Million)
Figure 20.7 Funding and Investment Analysis: Distribution of Funding Instances and Total Amount Invested by Geography (Country) (USD Million)
Figure 20.8 Most Active Players: Distribution by Number of Funding Instances
Figure 20.9 Most Active Players: Distribution by Total Amount Raised (USD Million)
Figure 20.10 Leading Investors: Distribution by Number of Funding Instances
Figure 20.11 Leading Investors: Distribution by Amount Invested (USD Million)
Figure 21.1 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Company Size
Figure 21.2 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Type of Expression System Used
Figure 21.3 Biopharmaceutical Contract Manufacturers: Global Production Capacity by Location of Manufacturing Facilities
Figure 21.4 Biopharmaceutical Contract Manufacturing Capacity in North America
Figure 21.5 Biopharmaceutical Contract Manufacturing Capacity in Europe
Figure 21.6 Biopharmaceutical Contract Manufacturing Capacity in Asia-Pacific

Figure 21.7Biopharmaceutical Contract Manufacturing Capacity in Rest of the World

Figure 22.1 Global Demand for Biopharmaceuticals, till 2035 (in kilograms)
Figure 22.2 Global Demand for ADC Therapeutics, till 2035 (in kilograms)
Figure 22.3 Global Demand for Cell Therapies, till 2035 (in terms of Number of Patients)
Figure 22.4 Global Demand for Cell Therapies, till 2035 (Billion Cells)
Figure 23.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 23.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 23.3 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 23.4 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 23.5 Total Cost of Ownership for Mid-sized Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 23.6 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 23.7 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 23.8 Total Cost of Ownership for Large / Very Large Biopharmaceutical Contract Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 24.1 Global Biopharmaceutical Contract Manufacturing Market, Historical Trends (Since 2018)
Figure 24.2 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Base Scenario (USD Billion)
Figure 24.3 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Conservative Scenario (USD Billion)
Figure 24.4 Global Biopharmaceutical Contract Manufacturing Market, Forecasted Estimates (till 2035), Optimistic Scenario (USD Billion)
Figure 25.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Service Offered, 2018, Current Year and 2035
Figure 25.2 Biopharmaceutical Contract Manufacturing Market for API Manufacturing, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 25.3 Biopharmaceutical Contract Manufacturing Market for FDF Manufacturing, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Biologic Manufactured, 2018, Current Year and 2035
Figure 26.2 Biopharmaceutical Contract Manufacturing Market for Antibodies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.3 Biopharmaceutical Contract Manufacturing Market for Cell Therapies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 26.4 Biopharmaceutical Contract Manufacturing Market for Vaccines, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Type of Expression System Used, 2018, Current Year and 2035
Figure 27.2 Biopharmaceutical Contract Manufacturing Market for Mammalian Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.3 Biopharmaceutical Contract Manufacturing Market for Microbial Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 27.4 Biopharmaceutical Contract Manufacturing Market for Other Expression Systems, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 28.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Scale of Operation, 2018, Current Year and 2035
Figure 28.2 Biopharmaceutical Contract Manufacturing Market for Preclinical / Clinical Operations, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 28.3 Biopharmaceutical Contract Manufacturing Market for Commercial Operations, Historical Trends (Since 2018 and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Company Size, 2018, Current Year and 2035
Figure 29.2 Biopharmaceutical Contract Manufacturing Market for Small Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.3 Biopharmaceutical Contract Manufacturing Market for Mid- sized Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 29.4 Biopharmaceutical Contract Manufacturing Market for Large and Very Large Companies, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.1 Biopharmaceutical Contract Manufacturing Market: Distribution by Geography, 2018, Current Year and 2035
Figure 30.2 Biopharmaceutical Contract Manufacturing Market in North America, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.3 Biopharmaceutical Contract Manufacturing Market in the US, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.4 Biopharmaceutical Contract Manufacturing Market in Canada, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.5 Biopharmaceutical Contract Manufacturing Market in Europe, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.6 Biopharmaceutical Contract Manufacturing Market in Italy, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.7 Biopharmaceutical Contract Manufacturing Market in Germany, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.8 Biopharmaceutical Contract Manufacturing Market in France, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.9 Biopharmaceutical Contract Manufacturing Market in Spain, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.10 Biopharmaceutical Contract Manufacturing Market in the UK, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.11 Biopharmaceutical Contract Manufacturing Market in Rest of Europe, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.12 Biopharmaceutical Contract Manufacturing Market in Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.13 Biopharmaceutical Contract Manufacturing Market in China, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.14 Biopharmaceutical Contract Manufacturing Market in India, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.15 Biopharmaceutical Contract Manufacturing Market in South Korea, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.16 Biopharmaceutical Contract Manufacturing Market in Japan, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.17 Biopharmaceutical Contract Manufacturing Market in Rest of Asia-Pacific, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.18 Biopharmaceutical Contract Manufacturing Market in Latin America, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.19 Biopharmaceutical Contract Manufacturing Market in Middle East and North Africa, Historical Trends (Since 2018) and Forecasted Estimates (till 2035) (USD Billion)
Figure 30.20 Biopharmaceutical Contract Manufacturing Market: Distribution by Leading Players (USD Billion)
Figure 31.1 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Market (USD Billion)
Figure 31.2 Overall Share of Virtual Biopharmaceutical Companies in the Biopharmaceutical Contract Manufacturing Market in 2023 (USD Billion)
Figure 32.1 Biopharmaceutical Contract Manufacturing: SWOT Analysis
Figure 32.2 Global Biopharmaceuticals Market: Distribution of Number of FDA Approvals by Year, 2005-2022
Figure 32.3 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 35.1 Concluding Remarks: Overall Market Landscape
Figure 35.2 Concluding Remarks: Partnerships and Collaborations
Figure 35.3 Concluding Remarks: Mergers and Acquisitions
Figure 35.4 Concluding Remarks: Funding and Investments
Figure 35.5 Concluding Remarks: Recent Expansions
Figure 35.6 Concluding Remarks: Capacity Analysis
Figure 35.7 Concluding Remarks: Demand Analysis
Figure 35.8 Concluding Remarks: Market Forecast and Opportunity Analysis (I/II)
Figure 35.9 Concluding Remarks: Market Forecast and Opportunity Analysis (II/II)

Biologics Contract Manufacturing Market by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions : Industry Trends and Global Forecasts, Till 2035

Description

Table of Contents

List of Tables

BIOLOGICS CONTRACT MANUFACTURING MARKET: OVERVIEW

BIOLOGICS CONTRACT MANUFACTURING MARKET: GROWTH AND TRENDS

BIOLOGICS CONTRACT MANUFACTURING MARKET: KEY INSIGHTS

BIOLOGICS CONTRACT MANUFACTURING MARKET: KEY SEGMENTS

BIOLOGICS CONTRACT MANUFACTURING MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

ADDITIONAL BENEFITS

TABLE OF CONTENTS

1. PREFACE

2. RESEARCH METHODOLOGY

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

4. EXECUTIVE SUMMARY

5. INTRODUCTION

6. MARKET LANDSCAPE

7. REGIONAL CAPABILITY ANALYSIS

8. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN NORTH AMERICA

9. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN EUROPE

10. BIOPHARMACEUTICAL CONTRACT MANUFACTURING IN ASIA-PACIFIC AND REST OF THE WORLD

11. NICHE BIOPHARMACEUTICAL SECTORS

12. CASE STUDY: OUTSOURCING OF BIOSIMILARS

13. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULE DRUGS / THERAPIES

14. CASE STUDY: IN-HOUSE MANUFACTURING

15. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

16. BIG PHARMA INITIATIVES

17. PARTNERSHIPS AND COLLABORATIONS

18. MERGERS AND ACQUISITIONS

19. RECENT EXPANSIONS

20. RECENT DEVELOPMENTS

21. CAPACITY ANALYSIS

22. DEMAND ANALYSIS

23. TOTAL COST OF OWNERSHIP FOR BIOPHARMACEUTICAL CONTRACT MANUFACTURING ORGANIZATIONS

24. GLOBAL BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET

25. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF SERVICE OFFERED

26. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF BIOLOGIC MANUFACTURED

27. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY TYPE OF EXPRESSION SYSTEM USED

28. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SCALE OF OPERATION

29. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY COMPANY SIZE

30. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY GEOGRAPHY

31. BIOPHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY LEADING PLAYERS

32. CASE STUDY: VIRTUAL PHARMACEUTICAL COMPANIES

33. SWOT ANALYSIS

34. FUTURE OF THE BIOPHARMACEUTICAL CMO MARKET

35. CONCLUSION

36. EXECUTIVE INSIGHTS

37. APPENDIX I: TABULATED DATA

38. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS

39. APPENDIX III: DETAILS OF PARTNERSHIPS AND COLLABORATIONS

List of Tables

List of Figures